Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Other Financing Activities
Financing cash flows not reported separately.
Forte Biosciences, Inc.NASDAQ: FBRX
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities growth accelerates
Q1 FY2026 other financing activities of $27K (cash outflow) rose 80.0% year over year, ahead of the -96.4% change in trailing-twelve-month other financing activities. Sequentially, it rose 350.0% from the prior quarter.
Context
- Other financing activities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +80.0% holds above the trailing-twelve-month pace of -96.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (7.47M) USD
- Year-over-year change
- -554.1%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.47M) | -554.1% |
| FY2024 | 2024-12-31 | (1.14M) | -2495.5% |
| FY2023 | 2023-12-31 | (44K) | -466.7% |
| FY2022 | 2022-12-31 | 12K | +111.3% |
| FY2021 | 2021-12-31 | (106K) | — |
Other Financing Activities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -96.4% is the 6th highest of 9, against a peer median of -70.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $9.92M USD | -9.8% | — | — |
| LTM Mar 2026 | $5.49M USD | +8.4% | — | 86.9% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $655.32K USD | -61.0% | — | — |
| LTM Mar 2026 | CHF 413.44K CHF | -102.6% | — | — | |
| LTM Mar 2026 | $217K USD | -79.2% | — | 1.2% | |
| LTM Mar 2026 | $41K USD | -96.4% | — | — | |
| LTM Mar 2026 | $25K USD | +31.6% | — | 4.8% | |
| LTM Mar 2026 | $7K USD | — | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| Peer median (excluding FBRX) | — | -70.1% | — | 4.8% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (69.38M) |
| Depreciation & Amortization | 36K | 0 | 9K | 39K | 64K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 1.04M |
| Stock-Based Compensation | 4.21M | 4.02M | 3.28M | 3.1M | 6.26M |
| Change in Working Capital | 720K | 1.68M | (392K) | 1.76M | 11.37M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (294K) | 207K | 271K | 3.02M | 5.54M |
| Other Working Capital | 1.01M | 1.47M | (663K) | (1.26M) | 5.83M |
| Other Non-Cash Items | 61K | 0 | (131K) | (158K) | (237K) |
| Operating Cash Flow | (16.68M) | (8.19M) | (28.71M) | (30.75M) | (50.88M) |
| Capital Expenditures | 0 | 0 | (88K) | (37K) | (116K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (9.97M) | (35.96M) | 0 |
| Sales of Investments | 0 | 0 | 10.1M | 0 | 36.35M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 47K | (35.99M) | 36.23M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 62K | 7.23M | 24.74M | 53M | 76.83M |
| Common Stock Repurchased | 0 | 0 | 0 | (1K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (106K) | 12K | (44K) | (1.14M) | (7.47M) |
| Financing Cash Flow | (44K) | 7.24M | 24.68M | 51.86M | 69.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.72M) | (944K) | (3.98M) | (14.88M) | 54.71M |
| Free Cash Flow | (16.68M) | (8.19M) | (28.79M) | (30.78M) | (51M) |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.